| pubmed-article:14523275 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14523275 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:14523275 | lifeskim:mentions | umls-concept:C1522405 | lld:lifeskim |
| pubmed-article:14523275 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:14523275 | lifeskim:mentions | umls-concept:C1519043 | lld:lifeskim |
| pubmed-article:14523275 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:14523275 | pubmed:dateCreated | 2003-10-2 | lld:pubmed |
| pubmed-article:14523275 | pubmed:abstractText | To define the tolerated dose of recombinant interleukin-2 (rIL-2) in HIV-infected children (part A), and to determine the safety and immunologic effects of the tolerated rIL-2 dose in a cohort of HIV-infected children (part B). | lld:pubmed |
| pubmed-article:14523275 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14523275 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14523275 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14523275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14523275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14523275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14523275 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14523275 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:14523275 | pubmed:issn | 0269-9370 | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:BugterM LML | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:RathoreMobeen... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:DouglasSteven... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:LevinMyron... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:PittJaneJ | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:FentonTerence... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:McFarlandEliz... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:MuresanPetron... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:DeveikisAudra... | lld:pubmed |
| pubmed-article:14523275 | pubmed:author | pubmed-author:PACTG 299... | lld:pubmed |
| pubmed-article:14523275 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14523275 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:14523275 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:14523275 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14523275 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14523275 | pubmed:pagination | 2181-9 | lld:pubmed |
| pubmed-article:14523275 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:meshHeading | pubmed-meshheading:14523275... | lld:pubmed |
| pubmed-article:14523275 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14523275 | pubmed:articleTitle | Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. | lld:pubmed |
| pubmed-article:14523275 | pubmed:affiliation | Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, USA. | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:14523275 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14523275 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14523275 | lld:pubmed |
